<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26380">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763319</url>
  </required_header>
  <id_info>
    <org_study_id>MOR208C204</org_study_id>
    <secondary_id>2014-004689-11</secondary_id>
    <nct_id>NCT02763319</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <acronym>B-MIND</acronym>
  <official_title>A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety and efficacy of MOR208 with BEN versus RTX
      with BEN in adult patients with relapsed of refractory DLBCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, two-arm, multicentre, open-label phase II/III efficacy and safety
      study of MOR208 in combination with BEN versus RTX in combination with BEN given to adult
      patients who have relapsed after or are refractory to at least one but no more than three
      prior systemic therapies and have failed, or are not candidates for HDC and ASCT, and have
      thus exhausted their therapeutic options of demonstrated clinical benefit. At least one
      prior therapy line must have included a CD20-targeted therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 4 yrs</time_frame>
    <description>To determine the efficacy of a combination of MOR208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in adult patients with R-R DLBCL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression (TTP)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to next treatment (TTNT)</measure>
    <time_frame>From date of randomization assessed up to 4 yrs</time_frame>
    <description>To determine efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>assessed up to 4 yrs</time_frame>
    <description>Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QoL)</measure>
    <time_frame>assessed up to 4 yrs</time_frame>
    <description>EORTC QLQ-C30 questionnaire will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients developing MOR208 antibodies</measure>
    <time_frame>assessed up to 2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration of MOR208 (Cmax)</measure>
    <time_frame>assessed up to 2 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent trough concentration (Cpd) of MOR00208</measure>
    <time_frame>assessed up to 2 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>MOR208 and bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR208 and bendamustine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab and bendamustine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab and bendamustine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab (RTX)</intervention_name>
    <description>Rituximab: Dose: 375 mg/m2 IV</description>
    <arm_group_label>Rituximab and bendamustine</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>Mab Thera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR208</intervention_name>
    <description>MOR208: MOR208 dose: 12 mg/kg intravenously (IV)</description>
    <arm_group_label>MOR208 and bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine (BEN)</intervention_name>
    <arm_group_label>MOR208 and bendamustine</arm_group_label>
    <arm_group_label>Rituximab and bendamustine</arm_group_label>
    <other_name>Levact/Treanda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Age ≥18 years

          2. Histologically confirmed diagnosis, according to the World Health Organization (WHO,
             2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma
             with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease
             transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent
             pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a
             DLBCL relapse subsequent to DLBCL treatment.

          3. Fresh tumour tissue for central pathology review must be provided as an adjunct to
             participation in this study. Should it not be possible to obtain a fresh tumour
             tissue sample, archival paraffin embedded tumour tissue acquired ≤3 years prior to
             screening for this protocol must be available for this purpose.

          4. Patients must have:

               1. relapsed or refractory DLBCL

               2. at least one bidimensionally measurable disease site. The lesion must have a
                  greatest transverse diameter of ≥1.5 cm and greatest perpendicular diameter of
                  ≥1.0 cm at baseline. The lesion must be positive on PET scan

               3. received at least one, but no more than three previous systemic therapy lines
                  for the treatment of DLBCL. At least one previous therapy line must have
                  included a CD20-targeted.

               4. ECOG 0 to 2

          5. Patients after failure of ASCT or patients considered in the opinion of the
             investigator currently not eligible for HDC with subsequent ASCT.

          6. Patients must meet the following laboratory criteria at Screening:

               1. ANC ≥1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL)

               2. PLTs ≥90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and
                  absence of active bleeding

               3. total serum bilirubin ≤2.5 × ULN unless secondary to Gilbert's syndrome (or
                  pattern consistent with Gilbert's) or documented liver involvement by lymphoma.
                  Patients with Gilbert's syndrome or documented liver involvement by lymphoma may
                  be included if their total bilirubin is ≤5 x ULN

               4. ALT, AST and AP ≤3 × ULN or &lt;5 × ULN in cases of documented liver involvement by
                  lymphoma

               5. serum creatinine ≤2.0 x ULN or creatinine clearance must be ≥40 mL/min
                  calculated using a standard Cockcroft-Gault formula (Cockroft &amp; Gault, 1976)

          7. For a female of childbearing potential (FCBP), a negative pregnancy test must be
             confirmed before enrolment. An FCBP must commit to take highly effective
             contraceptive precautions without interruption during the study and for 3, 6 or 12
             months after the last dose of MOR00208, BEN or RTX respectively, whichever is later.
             An FCBP must refrain from breastfeeding and donating blood or oocytes during the
             course of the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or
             RTX respectively, whichever is later. Restrictions concerning blood donations apply
             as well to females who are not of childbearing potential.

          8. Males must use an effective barrier method of contraception without interruption
             during the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or
             RTX respectively, whichever is later, if the patient is sexually active with an FCBP.
             Males must refrain from donating blood or sperm during study participation and for 3,
             6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is
             later.

          9. In the opinion of the investigator, the patients must:

               1. be able to comply with all study-related procedures, medication use, and
                  evaluations

               2. be able to understand and give informed consent

               3. not be considered to be potentially unreliable and/or not cooperative.

        EXCLUSION CRITERIA:

          1. Patients who have: any other histological type of lymphoma including, e.g., primary
             mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary
             refractory DLBCL, patients with known &quot;double/triple hit&quot; DLBCL genetics, CNS
             lymphoma involvement in present or past medical history

          2. Patients who had a major surgery less than 30 days prior to Day 1 dosing

          3. Patients who have, within 14 days prior to Day 1 dosing:

               1. not discontinued CD20-targeted therapy, chemotherapy, radiotherapy,
                  investigational anticancer therapy or other lymphoma-specific therapy

               2. received live vaccines

               3. required parenteral antimicrobial therapy for active, intercurrent systemic
                  infections

          4. Patients who:

               1. in the opinion of the investigator, have not recovered sufficiently from the
                  adverse toxic effects of prior therapies, major surgeries or significant
                  traumatic injuries

               2. were previously treated with CD19-targeted therapy or BEN

               3. have a history of previous severe allergic reactions to compounds of similar
                  biological or chemical composition to MOR00208, RTX, murine proteins or BEN, or
                  the excipients contained in the study drug formulations

               4. have undergone ASCT within a period of ≤3 months prior to signing the informed
                  consent form. Patients who have a more distant history of ASCT must exhibit full
                  haematological recovery before enrolment into the study.

               5. have undergone previous allogeneic stem cell transplantation

               6. concurrently use other anticancer or experimental treatments

          5. Prior history of malignancies other than DLBCL, unless the patient has been free of
             the disease for ≥3 years prior to Screening. Exceptions to the ≥3-year time limit
             include history of the following:

               1. basal cell carcinoma of the skin

               2. squamous cell carcinoma of the skin

               3. carcinoma in situ of the cervix, breast and bladder

             f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis [TNM]
             stage of T1a or T1b)

          6. Patients with:

               1. positive hepatitis B and/or C serology

               2. known seropositivity for or history of active viral infection with HIV

               3. evidence of active, severe uncontrolled systemic infections or sepsis

               4. a history or evidence of severely immunocompromised state

               5. a history or evidence of severe hepatic impairment (total serum bilirubin &gt; 3
                  mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver
                  involvement by lymphoma

               6. a history or evidence of clinically significant cardiovascular, cerebrovascular,
                  CNS and/or other disease that, in the investigator's opinion, would preclude
                  participation in the study or compromise the patient's ability to give informed
                  consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grzegorz Nowakowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman P Korolkiewicz, MD</last_name>
    <phone>+49 89 89927 0</phone>
    <email>roman.korolkiewicz@morphosys.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Zadar</city>
        <zip>23000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Chalon sur Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Kassel</city>
        <zip>34119</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10480</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morphosys Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>93510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Resarch Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Braga</city>
        <zip>4710243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4099001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4200072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Cadiz</city>
        <zip>1109</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bath</city>
        <zip>BA13NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Southend on Sea</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>April 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>bendamustine</keyword>
  <keyword>rituximab</keyword>
  <keyword>combination therapy</keyword>
  <keyword>CD19 monoclonal antibody</keyword>
  <keyword>transplant ineligible</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
